Geniposidic Acid Targeting FXR “S332 and H447” Mediated Conformational Change to Upregulate CYPs and miR‐19a‐3p to Ameliorate Drug‐Induced Liver Injury
Advanced Science · 2025
DOI: 10.1002/advs.202409107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Minqi Fan und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Traditional Chinese Medicine Syndrome, International Institute for Translational Chinese Medicine, Guangzhou University of Ch…. Hauptthemen laut MEDLINE: Receptors, Cytoplasmic and Nuclear, MicroRNAs, Chemical and Drug Induced Liver Injury, Diterpenes. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Foundation of Education Bureau of Guangdong Province, Science and Technology Program of Guangzhou.
Abstract (Originalsprache)
Drug‐induced liver injury (DILI), caused by chemical drugs and traditional Chinese medicine, often leads to severe outcomes like liver failure due to a lack of early detection markers. Farnesoid X receptor (FXR), a key regulator of bile acid (BA) and cholesterol metabolism, is a potential therapeutic target. This study investigates the pathogenesis, markers, and treatment strategies for DILI, focusing on the hepatoprotective effects of geniposidic acid (GPA) from Gardenia jasminoides J. Ellis . Using cellular and animal models of acute and chronic DILI induced by acetaminophen and triptolide, we explored GPA's mechanisms in BA and cholesterol metabolism. Lipidomic and BA analyses revealed that GPA alleviates DILI by enhancing bile acid synthesis and transport via FXR activation. Experiments using AAV‐shFXR, Fxr − / − mice and molecular assays demonstrated that GPA targets Ser332 and His447 on FXR ligand‐binding domain, promoting FXR nuclear translocation and initiating cytochrome P450 proteins (CYPs) transcriptional activation for BA metabolism. Additionally, miRNA sequencing and RNA‐pulldown assays showed that GPA‐activated FXR upregulates miR‐19a‐3p, binding to LXR 3'UTR to inhibit cholesterol production. These findings reveal the GPA‐FXR “structure‐target” relationship, highlighting a dual mechanism in which GPA promotes CYPs‐mediated bile acid metabolism and miR‐19a‐3p‐mediated cholesterol synthesis inhibition, providing a basis for FXR‐targeted DILI therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Traditional Chinese Medicine Syndrome, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
- Chinese Medicine Guangdong Laboratory, Hengqin, Guangdong, China.
ORCID-Profile: Caiyan Wang
Förderung
- National Natural Science Foundation of China
- Research Foundation of Education Bureau of Guangdong Province
- Science and Technology Program of Guangzhou
- Guangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines
Zitieren
APA
Fan, M., Xu, Y., Wu, B., Long, J., Liu, C., Liang, Z., Zhang, R., Liu, Z., & Wang, C. (2025). Geniposidic Acid Targeting FXR “S332 and H447” Mediated Conformational Change to Upregulate CYPs and miR‐19a‐3p to Ameliorate Drug‐Induced Liver Injury. Advanced Science. https://doi.org/10.1002/advs.202409107
Vancouver
Fan M, Xu Y, Wu B, Long J, Liu C, Liang Z, et al. Geniposidic Acid Targeting FXR “S332 and H447” Mediated Conformational Change to Upregulate CYPs and miR‐19a‐3p to Ameliorate Drug‐Induced Liver Injury. Advanced Science. 2025. doi:10.1002/advs.202409107
BibTeX
@article{Fan2025,
author = {Fan, Minqi and Xu, Yuanhang and Wu, Bingxin and Long, Jiachan and Liu, Caihong and Liang, Zuhui and Zhang, Rong and Liu, Zhongqiu and Wang, Caiyan},
title = {Geniposidic Acid Targeting FXR “S332 and H447” Mediated Conformational Change to Upregulate CYPs and miR‐19a‐3p to Ameliorate Drug‐Induced Liver Injury},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202409107}
}
EUVIMED